GSK Jemperli wins FDA priority review for rectal cancer
GSK says the U.S. regulator has accepted Jemperli, or dostarlimab, for priority review to treat a subtype of rectal cancer and set a February assessment deadline.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.